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Virus-like  particles  are  an  established  class of commercial  vaccine  possessing  excellent  function  and
proven  stability.  Exciting  developments  made  possible  by modern  tools  of  synthetic  biology  has  stim-
ulated  emergence  of  modular  VLPs,  whereby  parts  of one  pathogen  are  by  design  integrated  into  a
less harmful  VLP  which  has  preferential  physical  and  manufacturing  character.  This  strategy  allows  the
immunologically  protective  parts  of  a pathogen  to be displayed  on  the  most-suitable  VLP.  However,  the
ﬁeld  of modular  VLP  design  is  immature,  and  robust  design  principles  are  yet to  emerge,  particularly  for
larger  antigenic  structures.  Here  we  use  a  combination  of  molecular  dynamic  simulation  and  experiment
to reveal  two  key  design  principles  for  VLPs.  First,  the linkers  connecting  the  integrated  antigenic  module
with the  VLP-forming  protein  must  be well  designed  to  ensure  structural  separation  and  independence.
Second,  the  number  of antigenic  domains  on  the  VLP  surface  must  be  sufﬁciently  below  the maximum
such  that  a “steric  barrier”  to VLP  formation  cannot  exist.  This  second  principle  leads  to  designs  whereby
co-expression  of  modular  protein  with  unmodiﬁed  VLP-forming  protein  can  titrate  down  the  amount  of
antigen  on  the  surface  of the VLP,  to the  point  where  assembly  can  proceed.  In this  work  we  elucidate
these  principles  by displaying  the 18.1  kDa  VP8*  domain  from  rotavirus  on the  murine  polyomavirus  VLP,
and show  functional  presentation  of the  antigenic  structure.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Virus-like particles (VLPs) are an exciting new class of vaccine
hat have a unique and attractive set of properties including safety,
elf-adjuvanticity, developability, economy and the ability to be
ormulated for stability without a cold chain (reviewed in [1]). Their
mpact on human health is already evident through approved vac-
ines for Hepatitis B and E and for human papillomavirus. Enormous
esearch interest is now directed towards next-generation modu-
ar VLPs, which present parts of a disease-causing pathogen on or
ithin the particle formed from protein of an unrelated virus [2–4].
owever, the ﬁeld of modular VLP design is intellectually imma-
ure; design rules for modular VLPs do not yet exist in a way that
ould enable reliable a priori design of a new vaccine. While critical
nsights are emerging, for example that immune response quality
∗ Corresponding author. Tel.: +61 733653609; fax: +61 733469114.
E-mail address: a.middelberg@uq.edu.au (A.P.J. Middelberg).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.017
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article undepends critically on antigen structure [5], it is clear that consider-
able effort is still required to determine the principles that will lead
to reliable rather than serendipitous modular VLP design. Synthetic
biology and biomolecular engineering provide tools such as molec-
ular dynamic simulation and process design that will revolutionize
the ﬁeld of VLP vaccine design in coming years [6,7].
Globally, rotavirus continues to impose signiﬁcant burden of
disease, disproportionately on children. Almost half a million of
children under ﬁve years of age still die from rotavirus infec-
tion each year, mostly in developing countries [8]. Two  approved
live attenuated rotavirus vaccines are available; namely RotarixTM
(GlaxoSmithKline) and RotaTeqTM (Merck). Existing vaccines have
signiﬁcant limitations in the countries of greatest need [9,10]. The
affordability of these vaccines in low-income countries and the
increased risk of intussusception associated with rotavirus vaccines
underpin ongoing research for the next generation of low-cost and
safe subunit rotavirus vaccine. The advantages of VLPs mentioned
above make them an obvious technology to address this unmet
need. VLPs based on the entire virus comprise multiple proteins
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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aking them difﬁcult to process and characterize [11]. Modular
LPs presenting rotavirus sub-units are a promising approach that
rings manufacturing simplicity.
Polyomavirus has proven to be a remarkably efﬁcient and versa-
ile host for presentation of efﬁcacious antigen in a modular fashion
12–15]. We  have demonstrated that murine polyomavirus has par-
icular advantage as a modular platform because the protein VP1
an be expressed at high yield in bacterial cells [16] and that this
rotein can then be assembled, outside of a cell and under process
ontrol [17], in a way that is enabling for facile scale-up [18–20].
he result is a process having extremely low manufacturing cost
21] for a VLP that can be formulated to be thermostable [22] pre-
enting modules protective against viral [23,24] and bacterial [25]
athogens.
A limitation in the design of polyomavirus-based VLP vaccines
oncerns the size of the antigenic module presented. Peptide anti-
ens have been routinely incorporated [3,5,23,26,27] though entire
omains have proved more complex. Gleiter et al. [28] have pre-
ented a large enzyme on murine polyomavirus, though soluble
xpression yields were low and enzyme function was  reduced
resumably due to the incorrect structural conformation of the
nzyme. The preferred method for large antigen presentation on
olyomavirus has thus evolved to be one based on conjugation to an
lready-formed VLP, for example through electrostatic interaction
28] or chemical conjugation [29]. This “work-around” of conjuga-
ion increases complexity and hence reduces the competitiveness
f polyomavirus as a vaccine platform, but is necessary when the
rinciples of large-antigen modular design are not known in a way
hat allows robust and reliable vaccine design.
In this paper we successfully present the 18.1 kDa VP8* domain
30,31] from rotavirus on the murine polyomavirus VLP platform,
y expression of a single modular protein. Using molecular sim-
lation and coupled experiments, we uncover two  key design
rinciples that we anticipate will be enabling for the VLP ﬁeld in
eneral, and for the polyomavirus ﬁeld speciﬁcally. We  show that
he design of linkers is critical to enable functional separation of the
arge inserted module from the VLP protein, such that the struc-
ures of each are independently maintained. We  also show that
he incorporation of a large amount of large antigen on the sur-
ace of a capsomere, which is the basic building block of a VLP, can
nhibit VLP formation, simply because too much antigen is trying
o be present on the VLP. This “steric barrier” to VLP assembly was
ere overcome by co-expressing VP1 protein containing large anti-
en along with unmodiﬁed VP1 protein, i.e., by titrating down the
mount of modular antigen on the VLP surface. In this work we used
n insect cell expression platform, as this has led to human papil-
omavirus VLP vaccine approved for human use [32], and because
e wished to uncouple the questions of VLP design from those of
LP assembly in vitro. Our subsequent work will extrapolate the
rinciples learned here to the bacterial expression paradigm.
. Materials and methods
.1. Homology modelling of capsomeres
Homology models were created using Accelrys Discovery
tudio® 3.0. A model of each modular VP1-VP8* protein was  ﬁrst
onstructed using murine polyomavirus PDB template 1SID for VP1,
otavirus DS-1 strain VP8* core PDB template 2AEN, and Hendra
irus glycoprotein PDB template 2 × 9 M for Q25 and P6 linker
tructures. A single modular monomer was modelled within an
nmodiﬁed capsomere (i.e. 1 × VP1-VP8* and 4 × VP1), to maintain
uthentic VP1 structure and steric boundaries for antigen presen-
ation, as VP1 exists naturally as a capsomere. Model VP1-VP8*
as then further homology modelled into the modular capsomere (2015) 5937–5944
(i.e. 5 × VP1-VP8*), again using PDB 1SID for capsomere template.
Homology model of titrated VP1-VP8* was  constructed using two
VP1-VP8* monomers and three unmodiﬁed VP1 monomers, using
PDB 1SID as capsomere template.
2.2. Molecular dynamic simulation of modular VP1-VP8*
capsomeres
Molecular dynamics (MD) simulations for capsomeres were per-
formed using GROMACS version 4.6 with Gromos96 43a1 force ﬁeld
and the simple point charge (SPC) model for water. Each all-atom
molecular system constructed consisted of a single capsomere,
solvated in a cubic box (18 nm3), with solvent molecules added
randomly around polypeptide. The system was  solvated using the
SPC water model and was neutralized by adding Na+ counter ions.
Berendson method was  used to control temperature at 298 K with
time constant of 0.1 ps and pressure at 1 atm with coupling con-
stant of 1.0 ps. MD  algorithm was used with an integration time step
of 2 fs. Particle-mesh Ewald (PME) algorithm was  used to account
for electrostatic interactions. The cut-offs of neighbour atom list,
Coulomb potential, and Lennard–Jones (LJ) potential energies were
all set to 1.0 nm.  The initial velocities of particles were generated
according to a Maxwell distribution at 298.15 K. Then, 5000 steps
of steepest descent energy minimization were performed, followed
by 100 ps equilibration with position restraints on the protein
heavy atoms. The MD simulations were then performed for 20 ns
and this simulation process was performed in triplicate for each
capsomere. Simulations were performed on Australia’s National
Computational Infrastructure High Performance Cluster (HPC) Rai-
jin (Fujitsu Primergy HPC), scheduled with a PBS Professional job
scheduler, using 128 cores (Intel Xeon Sandy Bridge technology,
2.6 GHz) and 8 GB/core memory for approximately 100 h per sim-
ulation.
2.3. Plasmid construction
Transfer vector pBACTM-1 (Merck KGaA, Darmstadt, Germany)
carrying modiﬁed murine polyomavirus VP1 between BamHI and
XhoI restriction sites was  constructed to generate plasmid pBAC-
VP1. Murine polyomavirus VP1 sequence (M34958) was modiﬁed
by site-directed mutagenesis to insert NaeI and AfeI restriction
enzyme sites at positions 86 and 293 of VP1, respectively. The
gene fragment encoding human rotavirus outer capsid protein VP8*
(2AEN) with ﬂanking GGGGS (G4S) linker sequences was cloned
into AfeI site of pBAC-VP1, to generate pBAC-VP1-G4S-VP8*-G4S. To
construct pBAC-VP1-Q25-VP8*-P6, linker sequences Q25 (residues
QGVSDLVGLPNQICLQKTTSTILKP) and P6 (residues PAQCSE) were
inserted to ﬂank VP8* gene in plasmid pBAC-VP1-G4S-VP8*-G4S.
All constructs were veriﬁed by DNA sequencing at the Australian
Genome Research Facility (Brisbane, Australia).
2.4. Generation of recombinant baculoviruses
Recombinant baculoviruses were generated using the
ﬂashBACULTRATM system (Oxford Expression Technologies,
Oxford, UK). Spodoptera frugiperda Sf9 insect cells in Sf-900TM II
SFM (Life Technologies, California, USA) were seeded at 2.4 × 105
cells/well in a 24-well TC plate. Transfection reaction with a ratio
of 20:100 ng ﬂashBACULTRATM baculovirus DNA and each pBAC
construct was  prepared with Cellfectin® II (Life Technologies,
California, USA) and incubated at room temperature for 30 min
before dispensing onto the Sf9 cells. The plate was incubated at
27 ◦C for 5 h before replacing with fresh Sf-900TM II SFM sup-
plemented with 1× antibiotics-antimycotics and incubated at
cine 33
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7 ◦C for 7 days. Spent medium containing the budded virus was
arvested by centrifugation at 1500g for 5 min  at 4 ◦C.
.5. Protein expression
Sf9 cells at mid-log phase of 3 × 106 cells/mL were infected at
ultiplicity of infection (MOI) of 5 for protein production of VP1
nd modular VP1. To investigate the co-infection and co-expression
f VP1 and modular VP1-Q25-VP8*-P6, cultures were infected at
OI  1:1, 1:2, 1:3, 1:4 and 1:5 (VP1:VP1-Q25-VP8*-P6). Subsequent
o-expression cultures were infected at MOI  1:5 (VP1:VP1-Q25-
P8*-P6). All infected cultures were incubated at 27 ◦C in a shaking
ncubator at 120 rpm for 72 h. Cell density and viability were mon-
tored using trypan blue exclusion method and measured on the
ountessTM automated cell counter (Life Technologies, California,
SA). At harvest, cells were pelleted by centrifugation at 8000 × g
or 20 min  at 4 ◦C.
.6. VLP puriﬁcation
Puriﬁcation of VLPs using ultracentrifugation was as previously
escribed [33]. For VP1 VLPs, MOPS lysis buffer (50 mM MOPS,
00 mM NaCl, 0.002% (v/v) Tween80, pH 7.0) was used. Tris Base
ysis buffer (40 mM Tris Base, 50 mM NaCl, 0.01 mM CaCl2, 0.002%
v/v) Tween 80, pH 8.5) was used for modular VP1 VLPs.
.7. SDS–PAGE and Western blotting
Protein expression and puriﬁcation were analyzed using SDS-
AGE gel electrophoresis and Western blotting. Brieﬂy, 4–12%
is–Tris SDS-PAGE gels (Life Technologies, California, USA) were
un according to manufacturer’s instructions and visualized by
taining with SimplyBlueTM stain (Life Technologies, California,
SA). For Western blot analysis, the gel was transferred onto a
VDF membrane and probed with anti-VP1 antibody, followed
y goat anti-mouse antibody conjugated with horseradish perox-
dase (BD Biosciences, New Jersey, USA). Bands were visualized
ith enhanced chemiluminescence substrate using a Chemi-DocTM
RS+ imaging system (Bio-Rad, California, USA).
.8. Dot blot
Antigens (10 g) were applied onto a nitrocellulose membrane,
locked with 5% skim milk powder in 0.1% PBST buffer, and probed
ith either mouse polyclonal antibodies against VP1 or monoclonal
ntibodies (RV-5:2, [34]) against VP8*. Horseradish peroxidase-
onjugated goat anti-mouse antibody was used for detection via
hemiluminescence.
.9. Immunogold labelling
Puriﬁed VLP samples (2 g) were applied onto Formvar-coated
rids, left for 2 min, before rinsing with buffer (40 mM Tris Base,
0 mM NaCl, 0.01 mM CaCl2, 0.002% (v/v) Tween 80, pH 8.5) for
 min  to remove excess sample. Grids were blocked with 0.2% ﬁsh
kin gelatin and 0.2% BSA in buffer for 5 min. Ten times diluted
ouse anti-VP8* monoclonal antibody (RV-5:2) was applied and
ncubated for 30 min  at room temperature. After incubation, grids
ere washed four times with blocking buffer. Gold-conjugated goat
nti-mouse antibody was applied and incubated for 30 min  at room
emperature. After incubation, grids were rinsed with buffer for
our times and further washed with water twice. Grids were stained
ith 2% uranyl acetate for 2 min  before visualization under electron
icroscope. (2015) 5937–5944 5939
2.10. Analysis of VLPs
TEM was  performed as previously described. Infected cells
harvested at 72 h post infection were processed for TEM anal-
ysis as described by Lua et al. [35]. For puriﬁed VLP samples,
2 g sample was applied to a Formvar-coated 200-mesh copper
grid, stained and visualized as previously described [36]. For VLP
size distribution analysis, asymmetric ﬂow ﬁeld-ﬂow fractionation
(AF4) coupled with multi-angle light scattering was performed as
described previously [36].
3. Results and discussion
Flexible linkers with residues glycine and serine have been
widely used to link peptide or protein in the generation of hybrid
proteins [37,38]. Linker G4S was previously used to modularize
peptide epitope from group A streptococcus onto VLP [3]. In search
of naturally occurring protein domain linkers as seen in [37], linker
sequences Q25 (residues QGVSDLVGLPNQICLQKTTSTILKP) and P6
(residues PAQCSE) were derived from the stem region of glycopro-
tein G (O89343) preceding the beta-propellers globular head and
C-terminus region proceeding the globular head, respectively.
Homology modelled VP1-G4S-VP8*-G4S and VP1-Q25-VP8*-P6
capsomere structures were simulated using Gromacs molecular
dynamics software for 20 ns. Fig. 1 shows these structures before
and after simulation, demonstrating the change in structure at
the end of the simulation trajectory. Capsomere VP1-G4S-VP8*-
G4S is observed to be collapsing towards the capsomere, with the
18.1 kDa VP8* antigen module folding from above the capsomere
down along the side of the capsomere, potentially interacting with
VP1 structure, resulting in perturbation of the capsomere structure
and showing signiﬁcant instability. Capsomere VP1-Q25-VP8*-P6
however maintains presentation of the VP8* antigen module above
the capsomere with no predicted interaction between antigen and
capsomere structure, other than through the purposefully designed
linkers. There is no observed capsomere perturbation and the
structure of both VP8* antigen and capsomere appear stable. This
stability is likely due to the intrinsic ﬂexibility and length of the Q25
and P6 linkers, observed in Fig. 1, providing the antigen and cap-
somere with enough space to enable maintenance of independent
and non-interacting physicochemical characteristics. The short G4S
linkers on the VP1-G4S-VP8*-G4S capsomere design provide less
ﬂexibility and allow little space between antigen and capsomere
potentially activating undesired structural interactions.
Sf9 cultures were infected with recombinant baculoviruses car-
rying VP1, VP1-G4S-VP8*-G4S or VP1-Q25-VP8*-P6, separately, to
determine the expression of each protein. Fig. 2 shows the expres-
sion of the unmodiﬁed 42.5 kDa VP1 protein as predicted (Lane 2).
The theoretical molecular weights of VP1-G4S-VP8*-G4S and VP1-
Q25-VP8*-P6 are 61.3 kDa and 64.5 kDa, respectively. A protein
band of the correct molecular weight was detected for VP1-Q25-
VP8*-P6. However, no VP1-G4S-VP8*-G4S protein was detected by
either SDS-PAGE or Western blot analysis (Lane 3). Both cell den-
sity and cell morphology post infection suggested that all cultures
were well infected, and synchronous infections were achieved since
cell growth post infection halted almost immediately [39,40]. These
observations conﬁrmed that the linker design has an effect on the
expression of modular VP1-VP8* protein.
As reviewed by Chen et al., linkers may  improve biological
activity, increase expression yield, improve the folding and stabil-
ity of fusion proteins and target fusion proteins to speciﬁc sites
in vivo [38]. Molecular dynamic simulation predicts the mod-
ule VP1-G4S-VP8*-G4S to be unstable and this instability likely
affected the expression of the modular protein VP1-G4S-VP8*-G4S,
as the extent of expression of a hybrid protein is known to be
5940 L.H.L. Lua et al. / Vaccine 33 (2015) 5937–5944
Fig. 1. Effect of linkers on modularizing VP8* on VP1 capsomere. Homology models illustrating the modularization of antigenic module VP8* (red) and ﬂanking linkers (blue)
on  VP1. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web  version of this article.)
L.H.L. Lua et al. / Vaccine 33
Fig. 2. SDS-PAGE (A) and Western blot (B) analysis on the expression of modular VP1
constructs. Lanes: (L) molecular weight marker; (1) Sf9 non-infected cells; (2) VP1;
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at an MOI  ratio 1:5 to compensate for the lower expression of VP1-
F
(
b3) VP1-G4S-VP8*-G4S; (4) VP1-Q25-VP8*-P6. VP1 proteins migrated at predicted
W  42.5 kDa as indicated by arrow, and VP1-Q25-VP8*-P6 proteins migrated at
redicted MW 64.5 kDa (arrow).
equence- and structure-speciﬁc. For example, the effects of linker
equence on expression have been reported for transferrin-based
usion protein, where insertion of linker (G4S)3 did not yield
etectable expression but a helical linker [A(EAAAK)4A]2 gave an
1.2-fold higher production [41].
Ultrathin sections of infected cells were processed and viewed
nder TEM to examine if assembled VLPs could be observed in the
ig. 3. Electron micrographs of ultrathin sections of infected Sf9 cells. (A) An infected Sf9 ce
nm).  (B) Arrows indicate assembled VP1 VLPs. (C) Sf9 cell infected with recombinant bacu
aculovirus VP1-Q25-VP8*-P6 infected cell. (2015) 5937–5944 5941
nuclei of cells. As shown in Fig. 3A and B, VP1 VLPs accumulated
near the nuclear membrane in the nucleus, similar to previous
reports [33]. However, no modular VLP could be seen in cells
infected with recombinant baculovirus VP1-Q25-VP8*-P6 although
protein expression was conﬁrmed (Fig. 2). It appeared that suc-
cessful expression of a modular VP1-VP8* protein with permissive
linkers did not translate into successful VLP assembly.
We hypothesized that the high density of large antigen mod-
ules on the surface of each capsomere (Fig. 1) might have caused
a steric barrier, thus preventing VLP assembly. Fig. 4A and B
shows the speculative homology model after titrating down the
number of antigens present within each assembled capsomere,
as would be expected following co-expression of VP1-Q25-VP8*-
P6 and VP1. Adverse steric interaction between VP8* antigens is
signiﬁcantly reduced following reduction in the number of VP8*
modules per capsomere, potentially enabling a more stable cap-
somere. More importantly, the combination of ﬂexible purposefully
designed linkers and a reduction of modules was predicted to
prevent structural perturbation and interference removed by elim-
inating the steric barrier, allowing the assembly of capsomeres into
VLPs.
This hypothesis was tested by adopting the co-expression of
VP1 and VP1-Q25-VP8*-P6. A culture of Sf9 cells was co-infected
with both recombinant baculoviruses VP1 and VP1-Q25-VP8*-P6Q25-VP8*-P6. Both VP1 and VP1-Q25-VP8*-P6 proteins from the
co-expressed culture were detected (Fig. 4C, Lane 4). Under TEM,
assembled VLPs were observed in the nuclei of co-infected cells
ll showing the accumulation of VP1 VLPs in the nucleus, near the nuclear membrane
lovirus VP1-Q25-VP8*-P6. (D) VLP was not observed in the nucleus of recombinant
5942 L.H.L. Lua et al. / Vaccine 33 (2015) 5937–5944
Fig. 4. Co-expression strategy to obtain assembled modular VLPs presenting antigenic module VP8*. (A) Homology model showing the top view of a capsomere (5 VP1
monomers) containing 2 modules of VP8* (red). (B) Side view of a capsomere containing 2 modules of VP8* (red) presented on the surface by linker (blue). (C) Western blot
analysis of the expression and co-expression of modular VP1. Lanes: (L) molecular weight marker; (1) Sf9 non-infected cells; (2) VP1; (3) VP1-Q25-VP8*-P6; (4) co-expression
of  VP1 with VP1-Q25-VP8*-P6. (D and E) Electron micrographs of ultrathin section of Sf9 cells co-infected with recombinant baculoviruses VP1 and VP1-Q25-VP8*-P6. The
accumulation of VLPs was  observed in the nucleus of infected cell (red arrows). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
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nd these VLPs were similar in size and morphology to the VP1
LPs observed in Fig. 3A and B.
Attempts were made to purify VLPs from each expression
ulture of VP1, VP1-Q26-VP8*-P6 and co-expression VP1:VP1-Q26-
P8*-P6. Fig. 5 shows the banding pattern after caesium chloride
ensity gradient ultracentrifugation. A VLP band was  observed in
he tube for VP1. In comparison to the VP1 and co-expression
P1:VP1-Q26-VP8*-P6, no VLP band was observed for VP1-Q26-
P8*-P6 in the density gradient tube. This observation further
upports the hypothesis that VLP assembly is hindered when
 high density of large antigen is present on the surface of a
apsomere.
Co-expressed modular VLPs (VLP-VP8*) were puriﬁed from
he cells using caesium chloride density gradient ultracentrifu-
ation and analyzed under TEM (Fig. 6A). Immunogold labelling
ith anti-VP8* monoclonal antibodies conﬁrmed that VP8* anti-
en modules were presented on the surface of these puriﬁed
LPs (Fig. 6B). As shown in the dot blot analysis (Fig. 6C), the
nti-VP8* antibodies recognise only VP8* module and not the
P1 base. Both immunogold labelling and dot blot analysis with
he VP8*-speciﬁc rotavirus-neutralizing antibody [34] suggest that
odularized VP8* is conformational on the surface of the mod-
lar VLPs. Both VP1 VLPs and VLPs-VP8* were of similar size as
easured by asymmetric ﬂow-ﬁeld ﬂow fractionation coupled
ith multi-angle light scattering (Fig. 6D). The measured radii of
nmodiﬁed VP1 VLP and VLP-VP8* were 22.4 nm and 22.2 nm,
espectively.
Fig. 5. VLP puriﬁcation using caesium chloride density gradient ultracentrifuga-
tion. Intense bands (black arrows) containing VLPs were observed for VP1 and
co-expression samples. No band was  detected for VP1-Q25-VP8*-P6. Precipitates
(white arrows) were observed in VP1-Q25-VP8*-P6 and co-expression tubes.
L.H.L. Lua et al. / Vaccine 33 (2015) 5937–5944 5943
Fig. 6. Analysis of puriﬁed modular VLPs presenting VP8* modules, VLP-VP8*. (A) Transmission electron micrograph of ultracentrifuge-puriﬁed VLP-VP8* from co-expression.
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VB)  Immunogold labelling with anti-VP8* antibodies detected VP8* modules on the
f  VP1 expression; (2) puriﬁed VP1 VLPs; (3) cell lysate of co-expression; (4) puriﬁ
istribution of VP1 VLPs and VLP-VP8*. (For interpretation of the references to colo
. Conclusions
Computational tools were used to investigate the effect of
inker on modularizing large antigen on VLP. Results obtained from
olecular dynamics simulation were complementary and consis-
ent with the experimental data. The longer ﬂanking linkers, Q25
nd P6, provided ﬂexibility for the presentation of the rotavirus
P8* antigen module on VP1, leading to expression of the modular
roteins. However, the high density of large antigenic modules on
he surface of each capsomere hindered VLP assembly. Assembled
odular VLP was obtained using a new module titration strategy
y co-expressing unmodiﬁed VP1 with modular VP1-Q26-VP8*-P6.
his strategy decreased the number of antigenic module per cap-
omere, thus eliminating the steric barrier. By employing synthetic
iology and biomolecular engineering, we have demonstrated the
odularization and presentation of 18 kDa rotavirus large antigen
n the surface of a manufacturable VLP and, in doing so, revealed
wo potentially important principles for VLP design.
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